Home
by lalinea Tue Jan 18, 2022 11:15 pmevo vam izvodi, da se ne mucite da klikcete:
Myocarditis by the numbers
Before COVID-19 the incidence of myocarditis was between one and 10 cases per 100,000 people per year . Rates are highest in males between 18 and 30 years old. Interestingly, most cases of myocarditis in the highest risk group are in otherwise healthy and active people .
According to the U.S. Centers for Disease Control and Prevention , the risk of myocarditis after infection with COVID-19 is much higher, at 146 cases per 100,000. The risk is higher for males, older adults (ages 50+) and children under 16 years old. Soccer player Alphonso Davies, 21, of Canada’s national men’s team, was sidelined by heart inflammation after having COVID-19.
Post-vaccination myocarditis
Myocarditis following COVID-19 vaccination is rare and the risk is much smaller than the risks of cardiac injury linked to COVID-19 itself.
Based on a study out of Israel , the risk of post-vaccine myocarditis is 2.13 cases per 100,000 vaccinated, which is within the range usually seen in the general population. This study is consistent with others in the United States and Israel which put the overall incidence of post-vaccine myocarditis between 0.3 and five cases per 100,000 people .
The kids are alright
The highest incidence of myocarditis after vaccination with mRNA vaccines has occurred within three to four days after the second vaccination in males who are under age 30 . In pediatric data , the median age is 15.8 years, with most patients being male (90.6 per cent) and white (66.2 per cent) or Hispanic (20.9 per cent). Reliable data on booster shots in this age group is not yet available.
Most studies show a clear benefit of COVID-19 mRNA vaccination with respect to myocarditis. Only one study by Martina Patone, from the University of Oxford, and colleagues found more ambiguous results for those under 40 years of age based on myocarditis rates alone. However, if considering the other ill effects of infection with SARS-CoV-2 — both cardiac and not — there was still a strong benefit in immunizing younger people with COVID-19 vaccines other than Moderna, which research suggests has a higher risk for myocarditis than Pfizer’s vaccine .
How serious is it?
Over 80 per cent of myocarditis cases not related to COVID-19 or COVID-19 vaccination resolve spontaneously, while five per cent of patients die or require a heart transplant within one year of diagnosis.
Adults who develop myocarditis from COVID-19 have poorer outcomes than non-COVID-19 cases, including a higher risk of death. It should be noted that myocarditis associated with SARS-CoV-2 infection is just one of several heart conditions linked to COVID-19 with outcomes that are worse than non-COVID-19 cases.
In cases of myocarditis following COVID-19 vaccination, the vast majority of cases are mild and resolve quickly. In adults, 95 per cent of cases were deemed to be mild . Similarly, in children, 98.6 per cent are mild , and there has not been any reported need for mechanical heart support (extracorporeal membrane oxygenation, when blood is pumped outside the body to a heart-lung machine) or deaths. All children who had heart weakness had complete normalization of their heart function on followup.
vaccination campaign vs. 
vaccination campaign. 
